NS-2028 0280 is a novel oral multi-AGC

is a novel oral multi-AGC kinase inhibitor with potent pharmacodynamic and antitumor activity

Alda-1 administration leads to 2 and 10 differentially expressed proteins in the FCx and Hp of apoE−/− mice

InChiKey: OUQVKRKGTAUJQA-UHFFFAOYSA-N

Effects of RAGE-Specific Inhibitor FPS-ZM1 on Amyloid-β Metabolism and AGEs-Induced Inflammation and Oxidative Stress in Rat Hippocampus

NS-2028 0280 is a novel oral multi-AGCNS 2028 is a potent soluble guanylyl cyclase (sGC) inhibitor (Ki = 8 nM). It blocks sGC activity in murine cerebellum induced by S nitroso glutathione and NMDA (IC50 values are 17 and 20 nM respectively). NS 2028 also inhibits VEGF induced cGMP accumulation. Product information CAS Number: 204326 43 2 Molecular Weight: 269. 05 Formula: C9H5BrN2O3 Synonym: NS 2028 NS2028 Chemical Name: 8 bromo 4H [1, 2, 4]oxadiazolo[3, 4 c][1, 4]benzoxazin 1 one